208 related articles for article (PubMed ID: 34878886)
1. Simian Immunodeficiency Virus SIVgsn-99CM71 Vpu Employs Different Amino Acids To Antagonize Human and Greater Spot-Nosed Monkey BST-2.
Yao W; Strebel K; Yamaoka S; Yoshida T
J Virol; 2022 Feb; 96(4):e0152721. PubMed ID: 34878886
[TBL] [Abstract][Full Text] [Related]
2. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
[TBL] [Abstract][Full Text] [Related]
3. Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.
Yoshida T; Koyanagi Y; Strebel K
J Virol; 2013 Dec; 87(24):13825-36. PubMed ID: 24109238
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel simian immunodeficiency virus with a vpu gene from greater spot-nosed monkeys (Cercopithecus nictitans) provides new insights into simian/human immunodeficiency virus phylogeny.
Courgnaud V; Salemi M; Pourrut X; Mpoudi-Ngole E; Abela B; Auzel P; Bibollet-Ruche F; Hahn B; Vandamme AM; Delaporte E; Peeters M
J Virol; 2002 Aug; 76(16):8298-309. PubMed ID: 12134035
[TBL] [Abstract][Full Text] [Related]
5. Some human immunodeficiency virus type 1 Vpu proteins are able to antagonize macaque BST-2 in vitro and in vivo: Vpu-negative simian-human immunodeficiency viruses are attenuated in vivo.
Shingai M; Yoshida T; Martin MA; Strebel K
J Virol; 2011 Oct; 85(19):9708-15. PubMed ID: 21775449
[TBL] [Abstract][Full Text] [Related]
6. Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses.
Lim ES; Malik HS; Emerman M
J Virol; 2010 Jul; 84(14):7124-34. PubMed ID: 20444900
[TBL] [Abstract][Full Text] [Related]
7. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
[TBL] [Abstract][Full Text] [Related]
8. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.
Jia B; Serra-Moreno R; Neidermyer W; Rahmberg A; Mackey J; Fofana IB; Johnson WE; Westmoreland S; Evans DT
PLoS Pathog; 2009 May; 5(5):e1000429. PubMed ID: 19436700
[TBL] [Abstract][Full Text] [Related]
9. Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates.
Chen CY; Shingai M; Welbourn S; Martin MA; Borrego P; Taveira N; Strebel K
J Virol; 2016 Dec; 90(24):11062-11074. PubMed ID: 27681141
[TBL] [Abstract][Full Text] [Related]
10. Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene.
Nikovics K; Dazza MC; Ekwalanga M; Mammano F; Clavel F; Saragosti S
PLoS One; 2012; 7(4):e35411. PubMed ID: 22530020
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface.
Dubé M; Paquay C; Roy BB; Bego MG; Mercier J; Cohen EA
Traffic; 2011 Dec; 12(12):1714-29. PubMed ID: 21902775
[TBL] [Abstract][Full Text] [Related]
12. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
[TBL] [Abstract][Full Text] [Related]
13. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
Rong L; Zhang J; Lu J; Pan Q; Lorgeoux RP; Aloysius C; Guo F; Liu SL; Wainberg MA; Liang C
J Virol; 2009 Aug; 83(15):7536-46. PubMed ID: 19474106
[TBL] [Abstract][Full Text] [Related]
14. Lack of adaptation to human tetherin in HIV-1 group O and P.
Yang SJ; Lopez LA; Exline CM; Haworth KG; Cannon PM
Retrovirology; 2011 Sep; 8():78. PubMed ID: 21955466
[TBL] [Abstract][Full Text] [Related]
15. Sites of action of HIV-1 Vpu in BST-2/tetherin downregulation.
Arias JF; Iwabu Y; Tokunaga K
Curr HIV Res; 2012 Jun; 10(4):283-91. PubMed ID: 22524176
[TBL] [Abstract][Full Text] [Related]
16. BST-2 mediated restriction of simian-human immunodeficiency virus.
Ruiz A; Lau D; Mitchell RS; Hill MS; Schmitt K; Guatelli JC; Stephens EB
Virology; 2010 Oct; 406(2):312-21. PubMed ID: 20708210
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.
Sauter D; Hué S; Petit SJ; Plantier JC; Towers GJ; Kirchhoff F; Gupta RK
Retrovirology; 2011 Dec; 8():103. PubMed ID: 22171785
[TBL] [Abstract][Full Text] [Related]
18. A small molecule compound IMB-LA inhibits HIV-1 infection by preventing viral Vpu from antagonizing the host restriction factor BST-2.
Mi Z; Ding J; Zhang Q; Zhao J; Ma L; Yu H; Liu Z; Shan G; Li X; Zhou J; Wei T; Zhang L; Guo F; Liang C; Cen S
Sci Rep; 2015 Dec; 5():18499. PubMed ID: 26669976
[TBL] [Abstract][Full Text] [Related]
19. Antiviral activity of the interferon-induced cellular protein BST-2/tetherin.
Tokarev A; Skasko M; Fitzpatrick K; Guatelli J
AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1197-210. PubMed ID: 19929170
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine, serine, or threonine residues within the BST-2 cytoplasmic domain.
Gustin JK; Douglas JL; Bai Y; Moses AV
J Biol Chem; 2012 Apr; 287(18):14837-50. PubMed ID: 22383521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
